Invivyd, Inc.

NasdaqGM IVVD

Invivyd, Inc. Gross Profit for the Trailing 12 Months (TTM) ending September 30, 2024: USD 12.65 M

Invivyd, Inc. Gross Profit is USD 12.65 M for the Trailing 12 Months (TTM) ending September 30, 2024, a 836.55% change year over year. Gross profit is the difference between revenue and the cost of revenue, representing the profit earned from core business operations.

Invivyd, Inc. Gross Profit for the Trailing 12 Months (TTM) ending September 30, 2023 was USD -1.72 M, a -870.62% change year over year.
Invivyd, Inc. Gross Profit for the Trailing 12 Months (TTM) ending September 30, 2022 was USD -177.00 K, a 99.48% change year over year.
Invivyd, Inc. Gross Profit for the Trailing 12 Months (TTM) ending September 30, 2021 was USD -34.03 M.

Key data

Date	Gross Profit	Operating Income	EBIT	EBITDA

NasdaqGM: IVVD

Invivyd, Inc.

CEO	Dr. Robert D. Allen Ph.D.
IPO Date	Aug. 6, 2021
Location	United States
Headquarters	1601 Trapelo Road
Employees	94
Sector	Healthcare
Industries Vaccines Biotechnology Clinical Trials Pharmaceuticals

Description

Adagio Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company's lead product candidate is the ADG20 (adintrevimab), a neutralizing antibody that is in Phase 3 clinical trials for the treatment and prevention of coronavirus disease. Adagio Therapeutics, Inc. has a collaboration agreement with Adimab, LLC for the discovery and optimization of proprietary antibodies; and the Scripps Research Institute to perform research activities to identify vaccine candidates for the prevention, diagnosis or treatment of influenza or beta coronaviruses. The company was incorporated in 2020 and is based in Waltham, Massachusetts.

Key trends

Past 5 years